When the nation experienced a spike in whooping cough cases last summer, doctors speculated that something was wrong with a popular children's vaccine.
Now, an increase in whooping cough cases among Minnesota grade-schoolers has become national evidence that the pertussis vaccine loses effectiveness before children receive booster doses at ages 11 or 12.
The Centers for Disease Control and Prevention (CDC) studied the number of whooping cough infections in Minnesota and Oregon and found a sharp increase among vaccinated children ages 7 to 10, starting in 2006. There was no comparable increase in cases among other age groups, according to a report published Monday in the journal Pediatrics.
The age-specific nature of the increase is the key evidence that the pertussis vaccine loses strength over time, said Sara Tartof, a lead author of the report and a former CDC epidemic intelligence officer.
Today's 7- to 10-year-olds were the first to receive the "acellular" version of the vaccine, which was recommended by federal health officials in 1997 because it appeared safer than the older "whole cell" version. The kids were, in essence, test cases for the new vaccine's long-term effectiveness.
"If it was just due to increased recognition or diagnosis [of whooping cough], you would see the increase across all age groups," she said. "But this was happening in this specific age group at this specific time."
The report noted, however, that other factors might be to blame, including an increase in diagnoses.
Whooping cough is known for causing coughing fits, followed by a low whooping noise when children try to inhale. Infections often are harshest in infants, and can lead to pneumonia and other complications. The coughing can be so severe that some children suffer fractured ribs. Infections were linked to the deaths of 18 children in the United States last year.